



## Supplementary figures



**Supplementary figure 1. LRA activity in supernatants of NK cells after various treatments.**

NK lymphoma cell line KHYG-1 was incubated with DMSO (0.5 %), Z-VAD-FMK (50  $\mu$ M), emricasan (50  $\mu$ M), agonistic NKp30 antibody (1  $\mu$ g/mL), or PMAi (10 ng/mL PMA and 1  $\mu$ g/mL ionomycin) for 4 h or 12 h (each condition n=4) after which supernatants were used on reporter cells TZM-bl that were subjected to luciferase assay. Data points are plotted as mean  $\pm$ SD from the biological replicates (n=4). (ns, non-significant: \*\*\*\*p < 0.0001; ANOVA)



**Supplementary figure 2. Full secretome analysis of pan-caspase inhibitor-treated NK cells.**

NK lymphoma cell line KHYG-1 was incubated with DMSO (0.5 %; light blue), Z-VAD-FMK (50  $\mu$ M; green), emricasan (50  $\mu$ M; red), agonistic NKp30 antibody (1  $\mu$ g/mL; dark blue), or PMAi (10 ng/mL PMA and 1  $\mu$ g/mL ionomycin; yellow) for 4 h or 12 h (each condition n=4) after which supernatants were collected and relative protein levels were analyzed by PEA Olink panels Inflammation I and Inflammation II. Heatmaps of all secreted proteins with significantly different protein levels among the five treatment groups at 4 h **(A)** and 12 h **(B)**.